Natco Pharma announced that it has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand POSANAT. This is the first time an injection version of this drug available in India. POSANAT will be available in 18.0 mg/ml strength, a formulation for intravenous (IV) use. Posaconazole Injection is sold in the USA market by Merck under its brand name of NOXAFIL.

Posaconazole injection is an antifungal agent & used in patients who are at high risk of developing infections due to being severely immunocompromised, such as associated with stem cell transplant or from chemotherapy.

Shares of the company gained Rs 17.75, or 2.26%, to trade at Rs 804.50. The total volume of shares traded was 25,812 at the BSE (10.28 a.m., Monday).